• India’s first CRISPR Covid-19 test, developed by the Tata Group and CSIR-IGIB, has been approved for use in India.


• The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from the Drug Controller General of India (DCGI) for commercial launch.

• This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus.

• CRISPR is a genome editing technology for diagnosing diseases. The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19.

• The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use.

• The Tata Group has worked closely with CSIR-IGIB and ICMR to create this high-quality test.


Mains Paper 3: Science and Tech

Prelims level: CRISPR test

Mains level: Key highlights about the CRISPR test

Subscribe to Get Weekly updates

Get daily current affair video, detailed current affairs PPT for quick revision and Free One Liner PDF directly in your inbox. Subscribe now to get this month's one liner for FREE.